Novo Holdings

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

INOSIM GmbH

Predictive Simulation in Pharma Production

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

JULABO GmbH

When Every Temperature Change Determines the Process

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Catalent Inc.